Exploring passive immunization therapies for COVID-19 management in rheumatic patients

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam

Research output: Contribution to journalLetterOtherpeer-review

Abstract

We extend our appreciation to Çimen Güneş et al. for their insightful retrospective study shedding light on the impact of coronavirus disease 2019 (COVID-19) on patients with rheumatic diseases. Their thorough retrospective assessment of over 10 000 patients provides invaluable insights into the frequency and mortality rates associated with COVID-19 in this vulnerable population. The study's findings unveil critical insights that demand thoughtful consideration in clinical practice. Firstly, the incidence of COVID-19 among patients with rheumatic diseases is significant, with more than a quarter of individuals testing positive for the virus during the study period. This underscores the heightened vulnerability of this patient cohort to SARS-CoV-2 infection, likely attributed to underlying immune dysregulation linked to their rheumatic conditions and the immunosuppressive therapies they receive.
Original languageEnglish
Article numbere15325
Number of pages3
JournalInternational Journal of Rheumatic Diseases
Volume27
Issue number9
DOIs
Publication statusPublished - Sept 2024

Cite this